Clinical Trials Browser

Phase 1/2 × Pancreatic Neoplasms × tremelimumab × Clear all

NCT02311361 2021-04-20

Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer

Phase 1/2 Completed

65 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms